Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM

CAR-T, bispecifics or ADCs in late-stage RRMM

Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI

Treatment of multiple myeloma in Turkey

Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma

Multiple myeloma in a resource constrained setting

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy

Management of multiple myeloma in a resource-constrained setting